Non-Exclusive Drug Discount Agreement for Clobetasol
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Clobetasol (ATC-Code nach WHO: D07AD01)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum quantity; actual revenue depends on uncertain prescription behavior and patient numbers.
Buyer may terminate the Open-House if exclusive agreements are concluded, ending existing non-exclusive agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jul 31, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Jul 2027
- Supply of Clobetasol (ATC D07AD01) medicinal products, excluding emulsion formulation.
- Non-exclusive discount agreement under §130a Abs. 8 SGB V.
Show full summary
Non-exclusive drug discount agreement for Clobetasol (ATC D07AD01) via Open-House model under §130a Abs. 8 SGB V. Open to all pharmaceutical companies meeting requirements; no exclusivity, no minimum purchase quantities, and no negotiations. Contract ends 31.07.2027. First submission deadline for 01.08.2025 start is 23.06.2025; later deadlines per attached schedule.
Risks
No minimum quantity; actual revenue depends on uncertain prescription behavior and patient numbers.
Buyer may terminate the Open-House if exclusive agreements are concluded, ending existing non-exclusive agreements.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as per §4 Abs. 18 AMG regarding the offered medicinal products.
Eligibility
- Must submit 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen' (self-declaration on non-existence of exclusion grounds).
Administrative
- Must submit 'Eigenerklärung Russlandsanktionen' (self-declaration on Russia sanctions).
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-Exclusive Drug Discount Agreement for Clobetasol
Non-exclusive rebate agreement for Clobetasol (excluding emulsion). Open-House model; no minimum volume guarantee. Contract ends 31.07.2027.
Location
Duration
Category
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Clobetasol (ATC-Code nach WHO: D07AD01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 29 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 348847-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum quantity; actual revenue depends on uncertain prescription behavior and patient numbers.
Buyer may terminate the Open-House if exclusive agreements are concluded, ending existing non-exclusive agreements.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications